UK Antibacterial (Antibiotics) Drugs Market Report 2022 to 2030

UK Antibacterial (Antibiotics) Drugs Market Analysis

$ 3999

UK Antibacterial (Antibiotics) Drugs Market is at around $1.32 Bn in 2023 and is projected to reach $1.54 Bn in 2030, exhibiting a CAGR of 2.2% during the forecast period. The market is growing due to factors such as the aging population, rising prevalence of infectious diseases, and technological advancements. The market is dominated by key players like Wockhardt UK Ltd, Teva Pharmaceuticals Industries Ltd, AstraZeneca plc, Pfizer Inc., Roche, Novartis AG, GlaxoSmithKline plc, Abbott Laboratories, Johnson & Johnson, Merck & Co., Inc., and Sanofi S.A.

ID: IN10GBPH005 CATEGORY: Pharmaceuticals GEOGRAPHY: UK AUTHOR: Aneri Parekh

Buy Now

UK Antibacterial (Antibiotics) Drugs Market Executive Summary

UK Antibacterial (Antibiotics) Drugs Market is at around $1.32 Bn in 2023 and is projected to reach $1.54 Bn in 2030, exhibiting a CAGR of 2.2% during the forecast period.

Treating illnesses caused by bacteria in the UK is the focus of the antibiotics market in the country. This market includes a broad spectrum of antibiotic medications, including those that treat common infections like skin, urinary tract, and respiratory infections. To effectively navigate this vital sector, players must have a thorough understanding of market trends and difficulties.

Growing awareness of antibiotic resistance and rising rates of bacterial infections are driving the UK antibiotics market, which is still growing. To address the issue of resistance and provide new formulations, major firms are concentrating on research and development. The market environment is shaped by government programs encouraging prudent antibiotic usage and strict regulatory restrictions. Effective antibiotic stewardship and long-term market growth require cooperation between pharmaceutical corporations and healthcare providers.

There has been a noticeable change in the antibiotic sector in recent years. Revenue from the market reached $50.91 Bn in 2023 and is anticipated to grow further. Infectious diseases and the development of new products are the main factors contributing to this expansion. The need for new antimicrobial formulations, increased R&D, and antibiotic prescriptions have all contributed to these advances. New antibiotics and urbanization have an impact on market expansion.

Wockhardt UK Ltd is the UK's leading generic pharmaceutical company, specializing in the production and distribution of generic and branded antibiotics. A wide range of medications, including aminoglycosides, macrolides, penicillin, cephalosporins, and fluoroquinolones, are available from Wockhardt UK Ltd. It offers contract manufacturing services, including antibiotic production, for other pharmaceutical firms in addition to their pharmaceuticals. With the opening of a new sterile production facility in Wrexham, North Wales, Wockhardt UK Ltd. has made major investments to increase its manufacturing capabilities in the UK. It is anticipated that this investment will help them further solidify their position in the UK antibiotics market.

UK antibacterial (antibiotics) drugs market

Market Dynamics

Market Growth Drivers:

Increasing Prevalence of Infectious Diseases: Antibiotic demand in the UK is driven by growing bacterial infections and drug-resistant strains. Pneumonia, urinary tract infections, and STDs continue to drive drug needs.

Aging Population: Due to reduced immune systems and comorbidities, the elderly are more susceptible to infections and need antibiotics more often. 11 Mn people in the UK are aged 65 or older.

Technological Advancements: Novel antibiotic formulations, greater potency, and decreased side effects boost market growth. Combination medicines and innovative drug delivery technologies improve antibiotic treatment, expanding the market.

Market Restraints:

Regulatory Issues: New antibiotic approval restrictions can hinder market expansion as it is complicated and expensive, requiring significant clinical trials and compliance with the UK regulatory criteria.

Treatment Alternatives: The availability of vaccinations and non-antibiotic therapy for certain infections may reduce antibiotic use. Proactive antibiotic stewardship and prudent antibiotic use could further reduce antibiotic consumption, affecting market growth.

Patent Expiration: After major antibiotic patents expire, generic producers may increase competition, putting pressure on branded antibiotic prices and market share. Pharmaceutical corporations may lose money and spend less on antibiotic development.

Healthcare Policies and Regulatory Landscape

Medical equipment, medications, and blood components are regulated in the UK by the Medicines and Healthcare Products Regulatory Agency (MHRA). The executive agency known as MHRA is sponsored by the Department of Health and Social Care. The regulatory agency reviews clinical research to make sure the drug is safe, effective, and meets manufacturing quality standards. If they are satisfied, a license or marketing authorization is given. This enables the license holder to offer the product for sale in the regions under the regulatory body's jurisdiction. Thorough regulatory assessments, extensive clinical trials, and adherence to the stringent safety and efficacy requirements set forth by the Medicines and Healthcare Products Regulatory Agency (MHRA). It takes a lot of time and resources to complete these processes, which occasionally results in delays and challenges when new drugs are introduced to the market.

Competitive Landscape

Key Players:

Wockhardt UK Ltd
Teva Pharmaceuticals Industries Ltd
AstraZeneca plc
Pfizer Inc.
Roche
Novartis AG
GlaxoSmithKline plc
Abbott Laboratories
Johnson & Johnson
Merck & Co., Inc.
Sanofi S.A.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

UK Antibacterial (Antibiotics) Drugs Market Segmentation

By Drug Class

Cephalosporins
Penicillin
Fluoroquinolone
Macrolides
Carbapenems
Aminoglycosides
Sulfonamides
7-ACA
Others

By Type

Branded Antibiotics
Generic Antibiotics

By Action Mechanism

Cell Wall Synthesis Inhibitors
Protein Synthesis Inhibitors
DNA Synthesis Inhibitors
RNA Synthesis Inhibitors
Mycolic Acid Inhibitors
Others

By Spectrum

Broad-spectrum Antibiotic
Narrow-spectrum Antibiotic

By Administration

Oral
Intravenous
Others

By Distribution Channel

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Others

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.